ARCHIVES

Letrozole cuts risk of recurrent breast cancer in post-menopausal women.

This article is from The Cancer Letter archive.

Vol. 29 No. 38 | October 17, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995

Mayo’s Regional Program – Keys To Success Are Service, Communications

December 9, 1977

Long-Term Effect Of One Phase III Trial: Benefit For Thousands Of Patients

November 27, 2009

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

June 5, 1992

Specter Remains Chairman Of Labor-HHS Subcommittee.

February 2, 2001

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012